United Kingdom· GB-APID-40942611000001102
Vydura 75mg oral lyophilisates
A rimegepant product containing rimegepant, registered in United Kingdom by Pfizer Ltd. The same ATC class is registered in 16 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Rimegepant is registered in 16 of 19 countries.
Countries holding a registration under ATC N02CD06 (rimegepant), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 11 of them publish a price we can compare per daily dose
Rimegepant · ATC N02CD06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rimegepant costs, country by country.
Normalised to the WHO defined daily dose (37.5 mg), the median price runs from $14.84 in Switzerland to $64.33 in United States — a ×4.3 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rimegepant · price per daily dose (37.5 mg)
USD · FX 28 Sept 2026
- US United States$64.33 (acquisition cost)
- IT Italy$18.89
- ES Spain$16.29
- CH Switzerland$14.84
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Rimegepant
- Manufacturer
- Pfizer Ltd
- Country
- United Kingdom (GB)
- ATC code
- N02CD06
- ATC class
- Rimegepant
- Defined daily dose
- 37.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 5
- gtin5415062389409
- gtin5415062389010
- gtin5415062389416
- gtin5415062389027
- gtin5415062134405
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
90 interactions on record for rimegepant.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rimegepant · interactions on record
90 records
- 9 severe
- 81 moderate
Most severe, free to view
- DexamethasoneH02AB02severe
- DabrafenibL01EC02severe
- LorlatinibL01ED05severe
- DabrafenibL01XE23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rimegepant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVydura 75 mgPfizer Europe MA
- SpainVYDURA 75 MG LIOFILIZADO ORALPfizer Europe Ma Eeig
- FranceVYDURA 75 mg, lyophilisat oralPFIZER EUROPE MA EEIG (BELGIQUE)
- IrelandVydura 75 mg oral lyophilisatePfizer Europe MA EEIG
- NetherlandsVydura 75 mg, lyofilisaat voor oraal gebruikPfizer Europe MA EEIG
- PolandVyduraPfizer Europe MA EEIG
- United StatesNURTEC ODTPfizer Laboratories Div Pfizer Inc
- SwitzerlandVydura 75 mg, Lyophilisat zum EinnehmenPfizer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vydura
- Liechtenstein · Vydura
- Norway · Vydura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc073f51-6855-4b0a-ba29-cf6237f4b1e7 GET /v1/drugs/cc073f51-6855-4b0a-ba29-cf6237f4b1e7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40942611000001102",
"desc": "Vydura 75mg oral lyophilisates (Pfizer Ltd)",
"form": "Oral lyophilisate",
"vpid": "40981211000001100",
"source": "dmd",
"vtm_id": "860758006",
"strength": "75 mg",
"substance": "Rimegepant",
"ingredient": "Rimegepant sulfate",
"supplier_code": "2082201000001106"
}See everything about rimegepant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.